2-((4-Amino-3-(6-cyclopropoxynaphthalen-2-yl)-1Hpyrazolo[3,4-d]pyrimidin-1-yl)methyl)-1,1,1,3,3,3-hexafluoropropan-2-ol

ID: ALA4584646

Chembl Id: CHEMBL4584646

PubChem CID: 122453086

Max Phase: Preclinical

Molecular Formula: C22H17F6N5O2

Molecular Weight: 497.40

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  Nc1ncnc2c1c(-c1ccc3cc(OC4CC4)ccc3c1)nn2CC(O)(C(F)(F)F)C(F)(F)F

Standard InChI:  InChI=1S/C22H17F6N5O2/c23-21(24,25)20(34,22(26,27)28)9-33-19-16(18(29)30-10-31-19)17(32-33)13-2-1-12-8-15(35-14-5-6-14)4-3-11(12)7-13/h1-4,7-8,10,14,34H,5-6,9H2,(H2,29,30,31)

Standard InChI Key:  RQWDDVSBYNIPPF-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA4584646

    ---

Associated Targets(Human)

HepG2 (196354 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

CDPK1 Calmodulin-domain protein kinase 1 (251 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SRC Tyrosine-protein kinase SRC (482 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 497.40Molecular Weight (Monoisotopic): 497.1286AlogP: 4.63#Rotatable Bonds: 5
Polar Surface Area: 99.08Molecular Species: NEUTRALHBA: 7HBD: 2
#RO5 Violations: HBA (Lipinski): 7HBD (Lipinski): 3#RO5 Violations (Lipinski):
CX Acidic pKa: 7.49CX Basic pKa: 3.65CX LogP: 4.16CX LogD: 3.90
Aromatic Rings: 4Heavy Atoms: 35QED Weighted: 0.39Np Likeness Score: -0.48

References

1. Vidadala RS, Rivas KL, Ojo KK, Hulverson MA, Zambriski JA, Bruzual I, Schultz TL, Huang W, Zhang Z, Scheele S, DeRocher AE, Choi R, Barrett LK, Siddaramaiah LK, Hol WG, Fan E, Merritt EA, Parsons M, Freiberg G, Marsh K, Kempf DJ, Carruthers VB, Isoherranen N, Doggett JS, Van Voorhis WC, Maly DJ..  (2016)  Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of Toxoplasmosis.,  59  (13): [PMID:27309760] [10.1021/acs.jmedchem.6b00760]

Source